Caseware UK (AP4) 2024.0.164 2024.0.164 2025-12-312025-12-312025-01-01falseNo description of principal activity1615truetruefalse 03879639 2025-01-01 2025-12-31 03879639 2024-01-01 2024-12-31 03879639 2025-12-31 03879639 2024-12-31 03879639 1 2025-01-01 2025-12-31 03879639 d:Director2 2025-01-01 2025-12-31 03879639 c:Buildings c:LongLeaseholdAssets 2025-01-01 2025-12-31 03879639 c:Buildings c:LongLeaseholdAssets 2025-12-31 03879639 c:Buildings c:LongLeaseholdAssets 2024-12-31 03879639 c:PlantMachinery 2025-01-01 2025-12-31 03879639 c:FurnitureFittings 2025-01-01 2025-12-31 03879639 c:OfficeEquipment 2025-01-01 2025-12-31 03879639 c:ComputerEquipment 2025-01-01 2025-12-31 03879639 c:ComputerEquipment 2025-12-31 03879639 c:ComputerEquipment 2024-12-31 03879639 c:ComputerEquipment c:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 03879639 c:OtherPropertyPlantEquipment 2025-01-01 2025-12-31 03879639 c:OtherPropertyPlantEquipment 2025-12-31 03879639 c:OtherPropertyPlantEquipment 2024-12-31 03879639 c:OtherPropertyPlantEquipment c:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 03879639 c:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 03879639 c:CurrentFinancialInstruments 2025-12-31 03879639 c:CurrentFinancialInstruments 2024-12-31 03879639 c:CurrentFinancialInstruments c:WithinOneYear 2025-12-31 03879639 c:CurrentFinancialInstruments c:WithinOneYear 2024-12-31 03879639 c:ShareCapital 2025-12-31 03879639 c:ShareCapital 2024-12-31 03879639 c:SharePremium 2025-01-01 2025-12-31 03879639 c:SharePremium 2025-12-31 03879639 c:SharePremium 2024-12-31 03879639 c:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 03879639 c:RetainedEarningsAccumulatedLosses 2025-12-31 03879639 c:RetainedEarningsAccumulatedLosses 2024-12-31 03879639 c:TaxLossesCarry-forwardsDeferredTax 2025-12-31 03879639 c:TaxLossesCarry-forwardsDeferredTax 2024-12-31 03879639 d:OrdinaryShareClass1 2025-01-01 2025-12-31 03879639 d:OrdinaryShareClass1 2025-12-31 03879639 d:OrdinaryShareClass1 2024-12-31 03879639 d:FRS102 2025-01-01 2025-12-31 03879639 d:Audited 2025-01-01 2025-12-31 03879639 d:FullAccounts 2025-01-01 2025-12-31 03879639 d:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 03879639 d:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 03879639 2 2025-01-01 2025-12-31 03879639 e:PoundSterling 2025-01-01 2025-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 03879639









NEXTMUNE LABORATORIES LTD









DIRECTORS' REPORT AND FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2025




 
NEXTMUNE LABORATORIES LTD
REGISTERED NUMBER: 03879639

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 5 
145,538
160,327

  
145,538
160,327

Current assets
  

Stocks
 6 
88,757
355,981

Debtors: amounts falling due within one year
 7 
708,348
382,766

Cash at bank and in hand
 8 
1,814,732
724,935

  
2,611,837
1,463,682

Creditors: amounts falling due within one year
 9 
(400,324)
(366,628)

Net current assets
  
 
 
2,211,513
 
 
1,097,054

Total assets less current liabilities
  
2,357,051
1,257,381

Provisions for liabilities
  

Deferred tax
 10 
-
(8,448)

  
 
 
-
 
 
(8,448)

Net assets
  
2,357,051
1,248,933


Capital and reserves
  

Called up share capital 
 11 
101
101

Share premium account
 12 
6,588,422
6,588,422

Profit and loss account
 12 
(4,231,472)
(5,339,590)

  
2,357,051
1,248,933


Page 1

 
NEXTMUNE LABORATORIES LTD
REGISTERED NUMBER: 03879639
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2025

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 11 September 2026.




P M Gurney
Director

The notes on pages 3 to 10 form part of these financial statements.

Page 2

 
NEXTMUNE LABORATORIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


General information

Nextmune Laboratories Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies (see note 3).

The following principal accounting policies have been applied:

 
2.2

Going concern

The statement of financial position shows that the company had net assets at the balance sheet date
of £2,357,051 (2024: £1,248,933). After reviewing the company's budget, at the time of approving
these financial statements, the directors have a reasonable expectation that the company has
adequate resources to continue in operational existence for a period of at least 12 months.

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the statement of income and retained earnings within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

Page 3

 
NEXTMUNE LABORATORIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

  
2.4

Revenue

Turnover is derived from the sale of products and the provision of services. Turnover represents the fair value of consideration received or receivable in respect of products or services supplied to third parties in the period, excluding sales related taxes and trade discounts. Turnover is recognised on sale of products when the significant risks and rewards of ownership of the products are transferred to the customer, this is usually when products are delivered and title passes to the customer. Turnover from the provision of services is recognised on services when the service has been performed.

 
2.5

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

 
2.7

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


Page 4

 
NEXTMUNE LABORATORIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.8

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

The estimated useful lives range as follows:

Long-term leasehold property
-
5
Years
Plant and machinery
-
3
to 10 years
Fixtures and fittings
-
3
to 10 years
Office equipment
-
3
to 10 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.9

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.10

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.11

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.12

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 5

 
NEXTMUNE LABORATORIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

3.


Judgments in applying accounting policies and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgments, estimates and assumptions that affect the amounts reported for assets and liabilities at the reporting date as well as the amounts reported for revenues and expenses during the year. It also requires management to exercise judgment in applying the company's accounting policies. The resulting accounting estimates will, by definition, seldom equal the related actual results.
The following are the company's key sources of estimation uncertainty:
Tangible assets
Tangible assets are depreciated over their useful lives taking into account residual values where appropriate. The actual lives of assets and residual values are assessed annually and may vary depending on a number of factors. In re-assessing the assets' lives, factors such as technological innovation, product life cycles and maintenance programmes are taken into account.
Impairment of debtors
The company makes an estimate of the recoverable value of trade and other debtors. When assessing impairment, management considers factors including the current credit rating of the debtor, the ageing profile and historical experience.


4.


Employees

The average monthly number of employees, including the directors, during the year was as follows:


        2025
        2024
            No.
            No.







Employees
16
15

Page 6

 
NEXTMUNE LABORATORIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

5.


Tangible fixed assets


Long-term leasehold property
Office fixtures and fittings
Laboratory equipment
Total

£
£
£
£



Cost or valuation


At 1 January 2025
207,551
47,920
297,061
552,532


Additions
-
-
31,508
31,508



At 31 December 2025

207,551
47,920
328,569
584,040



Depreciation


At 1 January 2025
141,304
47,164
203,737
392,205


Charge for the year on owned assets
18,002
756
27,539
46,297



At 31 December 2025

159,306
47,920
231,276
438,502



Net book value



At 31 December 2025
48,245
-
97,293
145,538



At 31 December 2024
66,247
756
93,324
160,327


6.


Stocks

2025
2024
£
£

Raw materials and finished goods
88,757
355,981


Page 7

 
NEXTMUNE LABORATORIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

7.


Debtors

2025
2024
£
£


Trade debtors
282,333
305,391

Amounts owed by group undertakings
60,851
4,293

Prepayments and accrued income
128,844
73,082

Deferred taxation
236,320
-

708,348
382,766



8.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
1,814,732
724,935



9.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
125,078
204,024

Other taxation and social security
114,623
64,759

Other creditors
5,485
5,295

Accruals and deferred income
155,138
92,550

400,324
366,628



10.


Deferred taxation




2025


£






At beginning of year
(8,448)


Utilised in year
244,768



At end of year
236,320

Page 8

 
NEXTMUNE LABORATORIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
 
10.Deferred taxation (continued)

The deferred taxation balance is made up as follows:

2025
2024
£
£


Tax losses carried forward
236,320
(8,448)


11.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



101 (2024 - 101) Ordinary  shares of £1.00 each
101
101



12.


Reserves

Share premium account

Represents premium received on issue of Share Capital.

Profit and loss account

The profit and loss surplus forms part of profits available for distribution.


13.


Pension commitments

The company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. Contributions  totalling £5,141 (2024: £5,295) were payable to the fund at the balance sheet date and are included in creditors.


14.


Related party transactions

The company has taken advantage of the exemption in FRS 102 from the requirement to disclose the transactions with group companies on the grounds that the company is a wholly owned subsidiary.


15.


Post balance sheet events

There have been no significant events affecting the Company since the year end.

Page 9

 
NEXTMUNE LABORATORIES LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

16.


Controlling party

The ultimate parent undertaking is Vimian Group AB, a company registered in Sweden. Copies of the report and accounts of that company are available from the registered office:
Riddargatan 19
SE-114 57 Stockholm
Sweden
The immediate parent undertaking is Nextmune Holding B.V, a company registered in the Netherlands. Copies of the report and accounts of that company are available from the registered office:
Vijzelweg 11
8243 PM Lelystad
The Netherlands


17.


Auditors' information

The auditors' report on the financial statements for the year ended 31 December 2025 was unqualified.

The audit report was signed on 15 September 2026 by Hetal Mistry (senior statutory auditor) on behalf of Nyman Libson Paul LLP.

 
Page 10